Ultramed successfully raised £100,000

This site uses cookies. By using this site you agree to receiving cookies. View Policy.

Successfully funded

Capital at risk

overfunded

Ultramed

317%

Raised: £317,540

Investors: 473

Target: £100,000

Equity: 17.47%

Pre-money valuation: £1,500,000

Ultramed is a health tech company, placing innovation and patient experience at the forefront of their strategy. Combining clinical NHS operative experience, they operate a suite of cloud based pre operative products. The aim is to reduce costs and free up health care resources.

£65m could be saved if the NHS adopted digital preoperative assessment
The NHS performs 10 million procedures per annum
The founding team has broad commercial and clinical skills
Initial funding of £130k has allowed products to be commercialised

Idea

Ultramed operates a suite of online patient completed pre-procedure assessment programs under the Ultraprep trademark. The aim is to reduce costs and free up health care resources.

In 2011 the Department of Health published an investigation into digital preoperative assessment. It suggested that £65 million could be saved each year if this was adopted by 20% of the NHS. Our research suggests it hasn't been, presenting the commercial opportunity. With increasing use of the internet and the NHS moving to digital processes, the time is now.

Pre-procedure or preoperative assessment is usually paper based and completed by a nurse. This can take up to an hour. We operate a suite of products, hosted in the cloud, which aims to be efficient for clinicians and patients while reducing costs. Patients enter their information, then share it with their health care provider.

The NHS performs 10 million procedures each year. Ultraprep includes assessment for operations, endoscopies, cardiac cath lab and interventional radiology procedures. We are trialling with a private sector company and we're in talks with the Department for International Trade for their export support programme.

We feel we've gained good traction in the market given the barriers to entry for innovative products in the NHS. New product ideas for development have been identified using the initial software platform.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

To see the rest of the Ultramed pitch, join now. It's free, quick and easy.

Due to financial regulations, you need to join our community to view the full investment opportunity.

Join

Already registered? Log in

Investments of this nature carry risks to your capital, including illiquidity, lack of dividends and dilution. Balance risk with a diversified portfolio. Read more. Approved as a financial promotion by Crowdcube Capital Limited, which is authorised and regulated by the Financial Conduct Authority.

Investment opportunities are not offers to the public and investors must be eligible Crowdcube members. Further restrictions and Crowdcube's limitation of liability are set out in the Investor Terms and Conditions. Please seek independent advice as required as Crowdcube does not give investment or tax advice.

Ultramed has been given advance assurance by HMRC that the proposed share issue is likely to qualify for Enterprise Investment Scheme (EIS) tax relief.

Tax relief is available to individuals only, with income tax relief currently set at 30 per cent of the cost of the shares for the tax year in which the investment was made. The tax reliefs can also reduce your Capital Gains Tax bill. Read More.

Availability of tax relief depends on your individual and the company’s ongoing circumstances and applicable law.

Idea

To see the rest of the Ultramed pitch, join now. It's free, quick and easy.

Risk warning

Investing

Raising

About us

Legal